Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:29:00 EDT Sat 11 Oct 2025
Enter Symbol
or Name
USA
CA



Q:FATE - FATE THERAPEUTICS - https://www.fatetherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FATE - Q1.81.48·1.671.01.635+0.0251.64,315.96,2798,0211.63  1.66  1.44013.50  0.661119:49:22Oct 0215 min RT 2¢

Recent Trades - Last 10 of 8021
Time ETExPriceChangeVolume
19:49:22Q1.59-0.0222
19:38:10Q1.5912-0.018810,000
19:23:20Q1.59-0.021,000
18:43:40Q1.59-0.0247
18:31:26Q1.59-0.02100
18:23:05Q1.5403-0.0697200
18:14:38Q1.51-0.10100
18:14:32Q1.51-0.1050
18:10:37Q1.51-0.1050
18:09:57Q1.63990.02992

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-10-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-09-03 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-08-25 08:00U:FATENews ReleaseFate Therapeutics to Present at Upcoming Investor Conferences
2025-08-12 16:01U:FATENews ReleaseFate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
2025-08-05 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-07-03 13:05U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-06-11 09:00U:FATENews ReleaseFate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
2025-05-30 16:30U:FATENews ReleaseFate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
2025-05-28 17:54U:FATENews ReleaseFate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
2025-05-13 16:01U:FATENews ReleaseFate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
2025-05-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-04-29 09:26U:FATENews ReleaseFate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
2025-04-14 08:00U:FATENews ReleaseFate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
2025-04-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-03-05 16:01U:FATENews ReleaseFate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
2025-03-04 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2025-02-14 16:01U:FATENews ReleaseFate Therapeutics to Present at Upcoming Investor Conferences
2025-02-04 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-01-03 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-12-09 16:01U:FATENews ReleaseFate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus